Navigation Links
Oncothyreon's PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover
Date:11/16/2009

SEATTLE, Nov. 16 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) (the "Company") today announced that the Company's product candidate PX-866, a PI-3 kinase inhibitor, has been selected by Windhover Information, Inc., as one of the Top 10 most promising oncology projects in development that is available for partnering.

The selection was made by an independent committee assembled by Windhover Information, a leading provider of business information products and services to senior executives in the pharmaceutical, biotechnology and medical device industries. As a selected company, Oncothyreon will present data on PX-866 at Windhover's Therapeutic Area Partnerships conference on November 17-19, 2009, in Boston, MA.

PX-866 is an inhibitor of the PI-3-kinase/PTEN/AKT pathway, an important survival signaling pathway that is activated in many types of human cancer. Oncothyreon is currently conducting a Phase 1 trial of PX-866 in patients with advanced metastatic cancer. Based upon the results seen in this trial to date, including the preliminary data presented at the American Society of Oncology Annual Meeting (ASCO) earlier this year, Oncothyreon has made the decision to move PX-866 into Phase 2 clinical development in the first half of 2010. The Phase 2 development program is currently expected to include two or more trials of PX-866 in combination with chemotherapy or other targeted agents and as a single agent.

"Preliminary results from our ongoing trial of PX-866 have demonstrated that the activity of the target, PI-3 kinase, can be down-regulated at doses well below the maximally tolerated dose identified in the intermittent dosing arm," said Robert L. Kirkman, M.D., President and Chief Executive Officer of Oncothyreon. "As reported at ASCO, we have also had several patients with prolonged stable disease
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
2. Oncothyreon files investigational new drug application for PX-866 oncology compound
3. Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
4. Oncothyreons PX-866 is effective in preclinical model of pulmonary fibrosis
5. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
6. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
7. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
8. ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase
9. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
10. CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform
11. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
(Date:1/14/2014)... 2014  3D Communications, a leading provider of strategic communications services to ... events in the United States and ... Cox , JD, is returning to the firm,s Washington, ... 3D after more than two years of service as Associate Commissioner ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... previously reported, communicated in late 2007 ... ... Biotech Products, L.P.,today modified prescribing information for PROCRIT(R) (Epoetin alfa),following guidance from ... within the erythropoiesis-stimulating agent,(ESA) class., Modifications to the label were based ...
... by the Environmental Protection Agency (EPA) to fine California ... nano-pesticides is being applauded by David Rejeski, the director ... should receive a big pat on the back for ... federal pesticide law that has been on the books ...
... FRANKLIN LAKES, N.J., March 7 BD (Becton,Dickinson and Company) ... that it would present at the following investor healthcare,conferences:, ... 13, 2008 8:45 a.m. Greenwich Mean Time (4:45 a.m. ... Company 28th Annual Healthcare Conference March 20, 2008 ...
Cached Biology Technology:Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 2Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 3Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 4Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 5Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 6Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 7
(Date:7/9/2014)... climate change shifts the geographic ranges in which animals ... has on their parasites. Does an increased range for ... well? , Not necessarily, says a team of UC ... Kuris. In a study published in the Journal ... for some species, the opposite may happen: Hosts may ...
(Date:7/9/2014)... NY, July 9, 2014Biofuels derived from the oils produced ... fossil fuels. To achieve this goal, optimization of cost ... open pond systems, is needed. Sapphire Energy has developed ... open pond algae cultivation systems, described in Industrial ... Inc., publishers. The article is available on the ...
(Date:7/9/2014)... URBANA, Ill. With over 100 diseases that can ... the top of the most wanted list? University of ... reason that more research is needed on the fungus ... associated with cool, damp growing conditions but Macrophomina ... hot and dry drought conditions. , "As the climate ...
Breaking Biology News(10 mins):Not at home on the range 2Not at home on the range 3Not at home on the range 4Controlling contamination in open algae ponds for biofuels 2Climate change provides good growing conditions for charcoal rot in soybeans 2Climate change provides good growing conditions for charcoal rot in soybeans 3
... of how an abundance of fossils have been marvellously preserved ... of Africa has been solved by a team of geologists ... have established that an ancient wind brought life to the ... the dead. Sarah Gabbott, Jan Zalasiewicz and colleagues investigated ...
... a strategic alliance for catalysis research, "Munich Catalysis." In addition ... aspect of this cooperation will be the development of innovative ... global demand for energy and base chemicals on a long-term ... to two million euros a year. The cooperation is based ...
... The Great Tit is a common garden bird of many ... thought of as fairly inquisitive but it has long been ... surroundings. Some birds known as "fast" or "proactive" ... or "reactive" birds are more cautious. The differences are ...
Cached Biology News:Up to 20 million euros for Munich Catalysis research cooperation 2Up to 20 million euros for Munich Catalysis research cooperation 3Bird-brained? Birds' personalities are correlated with their hormone levels 2
...
... An entire pressurized perfusion system ... in physiology, biophysics, electrochemistry, or general ... as little as 100 microliters of ... eight solutions in milliseconds from a ...
...
Request Info...
Biology Products: